Human Cell Based Drug Discovery
The current ‘gold standard’ for in vitro cell safety vs. toxicity assessment for hit-to-lead or lead assets is the mouse 3T3 fibroblast. In DBM’s view, this is antiquated and insufficient. For all of DBM’s hit-to-lead and lead small molecule assets, we perform the same bioassays that we offer to our customers in the menu-based offerings of our Online Store. We offer basic testing platforms in 2D culture format for a panel of different human tissue-derived primary cell cultures. One or more cell types from each tissue can be tested. Our offerings are menu-driven and, therefore, customizable for each customer.
For similar analysis of additional specialized cell types (hepatocytes, adipocytes, cardiomyocytes, neuronal cells, etc.), please also inquire on Custom Inquiry page for capabilities and more information.
Includes 3D biogel based TC analysis of asset on human primary polycystic kidney disease cell culture of choice.
Includes 2D TC-based assessment of three different primary cultures of human mixed cortical, mixed medullary, and proximal tubule-derived renal epithelial cells.
Includes 2D TC-based assessment of four different primary cultures of human large airway epithelial cells, small airway epithelial cells, lung microvascular endothelial cells and airway smooth muscle cells.
Includes 2D TC-based assessment of four different primary cultures of human arterial Endothelial cells, venous endothelial cells, microvascular endothelial cells and vascular smooth muscle cells.
Includes 2D TC-based assessment of two different primary cultures of human keratinocytes, melanocytes, and dermal fibroblasts.